Finance entity
Arcturus Therapeutics is most often covered alongside Apogee Therapeutics, which appears in 1 of these 2 stories. That works out to roughly 0.8 stories per week across an 18-day span. The 5 average consequence score is below the beat benchmark of 6.3 in the same window.
Last mentioned: Mar 19, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Arcturus Therapeutics is most often covered alongside Apogee Therapeutics, which appears in 1 of these 2 stories. That works out to roughly 0.8 stories per week across an 18-day span. The 5 average consequence score is below the beat benchmark of 6.3 in the same window. Source depth averages 2 original sources per story, versus 2.6 across the same-window beat baseline. Coverage clusters in earnings, which accounts for 1 of those 2, with the remainder spread across 1 other category. Arcturus Therapeutics appears in 2 tracked Finance stories published from March 2, 2026 through March 19, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 1573 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Arcturus Therapeutics. Shared-story counts are live from our verified record — not editorial picks.
A significant wave of analyst rating changes has hit the market, featuring a notable downgrade for boutique fitness giant Xponential Fitness and a bullish initiation for space leader Rocket Lab. These shifts underscore a broader institutional reassessment of growth trajectories across the fitness, aerospace, and biotechnology sectors.
Arcturus Therapeutics and Rigel Pharmaceuticals are preparing to report Q4 2025 results, highlighting a pivotal shift from clinical development to commercial execution. Investors are focused on Arcturus's mRNA vaccine rollout in Japan and Rigel's integration of its expanded oncology portfolio.
Arcturus Therapeutics is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
